Importance of Immunohistochemical Detection of Somatostatin Receptors

A. Zalatnai, Eszter Galambos, Eszter Perjési

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The long-acting somatostatin analogs represent important weapons in treatment protocols of patients with neuroendocrine tumors. Because these peptides preferentially bind to the specific somatostatin receptors, the targeted therapy requires detection of them. As one of the national consulting centers, here we present the results of the immunohistochemically positive neuroendocrine neoplasms diagnosed between 2010 and 2014. Twenty-four paraffin-embedded cases (14 females 10 men, 21–79 years) from different localizations were found to express somatostatin-receptor type 2 (SSTR2). None of the patients has received previous hormonal therapy. The immune reactions have shown membranous, cytoplasmic or mixed patterns. There was no correlation between the expression and the chromogranin A levels, the grades or the hormonal activity/inactivity of the given neoplasms. Our results show that the immunohistochemical detection of SSTR2 is a quick, reliable and effective tool that provides useful information to the oncologists for the therapeutic decision. Because the incidence of the neuroendocrine tumors is still low, centralized pathological units are needed to perform such technique.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalPathology and Oncology Research
DOIs
Publication statusAccepted/In press - Jun 3 2018

Fingerprint

Somatostatin Receptors
Neuroendocrine Tumors
Chromogranin A
Weapons
Clinical Protocols
Somatostatin
Paraffin
Neoplasms
Therapeutics
Peptides
Incidence
somatostatin receptor 2

Keywords

  • Immunohistochemistry
  • Neuroendocrine tumors
  • Somatostatin receptors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Importance of Immunohistochemical Detection of Somatostatin Receptors. / Zalatnai, A.; Galambos, Eszter; Perjési, Eszter.

In: Pathology and Oncology Research, 03.06.2018, p. 1-5.

Research output: Contribution to journalArticle

@article{5e953aa3f9374bafb530e3a7056ae136,
title = "Importance of Immunohistochemical Detection of Somatostatin Receptors",
abstract = "The long-acting somatostatin analogs represent important weapons in treatment protocols of patients with neuroendocrine tumors. Because these peptides preferentially bind to the specific somatostatin receptors, the targeted therapy requires detection of them. As one of the national consulting centers, here we present the results of the immunohistochemically positive neuroendocrine neoplasms diagnosed between 2010 and 2014. Twenty-four paraffin-embedded cases (14 females 10 men, 21–79 years) from different localizations were found to express somatostatin-receptor type 2 (SSTR2). None of the patients has received previous hormonal therapy. The immune reactions have shown membranous, cytoplasmic or mixed patterns. There was no correlation between the expression and the chromogranin A levels, the grades or the hormonal activity/inactivity of the given neoplasms. Our results show that the immunohistochemical detection of SSTR2 is a quick, reliable and effective tool that provides useful information to the oncologists for the therapeutic decision. Because the incidence of the neuroendocrine tumors is still low, centralized pathological units are needed to perform such technique.",
keywords = "Immunohistochemistry, Neuroendocrine tumors, Somatostatin receptors",
author = "A. Zalatnai and Eszter Galambos and Eszter Perj{\'e}si",
year = "2018",
month = "6",
day = "3",
doi = "10.1007/s12253-018-0426-4",
language = "English",
pages = "1--5",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Importance of Immunohistochemical Detection of Somatostatin Receptors

AU - Zalatnai, A.

AU - Galambos, Eszter

AU - Perjési, Eszter

PY - 2018/6/3

Y1 - 2018/6/3

N2 - The long-acting somatostatin analogs represent important weapons in treatment protocols of patients with neuroendocrine tumors. Because these peptides preferentially bind to the specific somatostatin receptors, the targeted therapy requires detection of them. As one of the national consulting centers, here we present the results of the immunohistochemically positive neuroendocrine neoplasms diagnosed between 2010 and 2014. Twenty-four paraffin-embedded cases (14 females 10 men, 21–79 years) from different localizations were found to express somatostatin-receptor type 2 (SSTR2). None of the patients has received previous hormonal therapy. The immune reactions have shown membranous, cytoplasmic or mixed patterns. There was no correlation between the expression and the chromogranin A levels, the grades or the hormonal activity/inactivity of the given neoplasms. Our results show that the immunohistochemical detection of SSTR2 is a quick, reliable and effective tool that provides useful information to the oncologists for the therapeutic decision. Because the incidence of the neuroendocrine tumors is still low, centralized pathological units are needed to perform such technique.

AB - The long-acting somatostatin analogs represent important weapons in treatment protocols of patients with neuroendocrine tumors. Because these peptides preferentially bind to the specific somatostatin receptors, the targeted therapy requires detection of them. As one of the national consulting centers, here we present the results of the immunohistochemically positive neuroendocrine neoplasms diagnosed between 2010 and 2014. Twenty-four paraffin-embedded cases (14 females 10 men, 21–79 years) from different localizations were found to express somatostatin-receptor type 2 (SSTR2). None of the patients has received previous hormonal therapy. The immune reactions have shown membranous, cytoplasmic or mixed patterns. There was no correlation between the expression and the chromogranin A levels, the grades or the hormonal activity/inactivity of the given neoplasms. Our results show that the immunohistochemical detection of SSTR2 is a quick, reliable and effective tool that provides useful information to the oncologists for the therapeutic decision. Because the incidence of the neuroendocrine tumors is still low, centralized pathological units are needed to perform such technique.

KW - Immunohistochemistry

KW - Neuroendocrine tumors

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=85047941513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047941513&partnerID=8YFLogxK

U2 - 10.1007/s12253-018-0426-4

DO - 10.1007/s12253-018-0426-4

M3 - Article

AN - SCOPUS:85047941513

SP - 1

EP - 5

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -